Recently, prostate cancer (PCa) diagnosis and disease monitoring have improved significantly. However, in Lithuania, approximately 2,000 men are diagnosed with PCa yearly. Prostate-specific antigen (PSA) is one of the most common diagnostic tools used for PCa in everyday clinical practice. This biomarker is specific for prostate tissue, but not for the disease; therefore, PSA diagnostic sensitivity is high, but specificity remains extremely low. However, genetic testing in conjunction with other screening tools can improve diagnostic efficiency and risk assessment of PCa.
A total of 30 PCa patients from National Cancer Institute were included in this study. Thirty-seven genes were selected for multigene testing based on their significance for disease development and interface with an increased risk of developing the disease (e.g. DNA damage response genes (DDR)). Next generation sequencing (NGS) technology was applied for genomic profile analysis of selected PCa cases. All identified mutations were validated by reviewing the results with Integrative Genomics Viewer (IGV). All identified genetic changes were classified as pathological, non-pathological, and risk factors. Though ClinVar is the major database used in clinical practice, detected variants were additionally checked in other databases (COSMIC, VarSome).
Pathological mutations, such as c.1813delA and c.470T>C were detected respectively in BRCA2 and CHEK2 genes. SNP associated with potential increased PCa risk accounted for 10.4% of all detected missense changes. Among them, risk-related single nucleotide variants in MSMB and RNASEL genes were the most common. At least one PCa risk-related SNP was observed for each patient. Furthermore, elderly patients with clinically significant PCa (Gleason 4+3 and 4+4) had a significantly higher number of risk-related PCa SNPs (p=0.03).
In conclusion, this genetic profiling revealed that pathological genetic alterations in PCa patients are predominantly observed in DDR genes, such as BRCA and CHEK2. We also noticed quite a high prevalence of SNPs related to a higher risk of the disease. Thus, the multigene diagnostic system in conjunction with clinical data has the potential to allow the accurate assessment of particularly heterogeneous PCa, proper prediction of disease risk, tumour aggressiveness, and reduce overdiagnosis of clinically insignificant cancer.